Cargando…

Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation

Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jing, Gao, Jie, Sun, Jing, Wang, Haiping, Sun, Huijuan, Huang, Qian, Zhang, Yao, Zhong, Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422021/
https://www.ncbi.nlm.nih.gov/pubmed/37576813
http://dx.doi.org/10.3389/fphar.2023.1106339
_version_ 1785089102148796416
author Lu, Jing
Gao, Jie
Sun, Jing
Wang, Haiping
Sun, Huijuan
Huang, Qian
Zhang, Yao
Zhong, Shuo
author_facet Lu, Jing
Gao, Jie
Sun, Jing
Wang, Haiping
Sun, Huijuan
Huang, Qian
Zhang, Yao
Zhong, Shuo
author_sort Lu, Jing
collection PubMed
description Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients (n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. Further studies were performed in animal experiments to determine the ascendancy of apolipoprotein A-I mimetic peptide (D-4F) on peritoneum, we found that D-4F administration reduced peritoneal fibrosis and peritoneal endothelial mesenchymal transformation (EMT) induced by high glucose peritoneal dialysate, such as N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA) expression decreased. In mechanism, D-4F can significantly inhibit Smad2/3 phosphorylation, which is the major pathway leading to fibrosis. Furthermore, D-4F treatment inhibited NADPH oxidase and thiobarbituric acid reactive substances (TBARS) expression, increased the activity of certain enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Finally, treatment with D-4F inhibits the expression of interleukins-6(IL-6), Interleukin-1β(IL-1β), and tumor necrosis factor-α(TNF-α). Taken together, based on the above research evidence, apoA-I and its peptide mimic may regulate the oxidative stress, TGF- β1/Smads signaling pathway and inflammatory response to reduce peritoneal fibrosis due to peritoneal dialysis.
format Online
Article
Text
id pubmed-10422021
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104220212023-08-13 Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation Lu, Jing Gao, Jie Sun, Jing Wang, Haiping Sun, Huijuan Huang, Qian Zhang, Yao Zhong, Shuo Front Pharmacol Pharmacology Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients (n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. Further studies were performed in animal experiments to determine the ascendancy of apolipoprotein A-I mimetic peptide (D-4F) on peritoneum, we found that D-4F administration reduced peritoneal fibrosis and peritoneal endothelial mesenchymal transformation (EMT) induced by high glucose peritoneal dialysate, such as N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA) expression decreased. In mechanism, D-4F can significantly inhibit Smad2/3 phosphorylation, which is the major pathway leading to fibrosis. Furthermore, D-4F treatment inhibited NADPH oxidase and thiobarbituric acid reactive substances (TBARS) expression, increased the activity of certain enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Finally, treatment with D-4F inhibits the expression of interleukins-6(IL-6), Interleukin-1β(IL-1β), and tumor necrosis factor-α(TNF-α). Taken together, based on the above research evidence, apoA-I and its peptide mimic may regulate the oxidative stress, TGF- β1/Smads signaling pathway and inflammatory response to reduce peritoneal fibrosis due to peritoneal dialysis. Frontiers Media S.A. 2023-07-28 /pmc/articles/PMC10422021/ /pubmed/37576813 http://dx.doi.org/10.3389/fphar.2023.1106339 Text en Copyright © 2023 Lu, Gao, Sun, Wang, Sun, Huang, Zhang and Zhong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lu, Jing
Gao, Jie
Sun, Jing
Wang, Haiping
Sun, Huijuan
Huang, Qian
Zhang, Yao
Zhong, Shuo
Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
title Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
title_full Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
title_fullStr Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
title_full_unstemmed Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
title_short Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
title_sort apolipoprotein a-i attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422021/
https://www.ncbi.nlm.nih.gov/pubmed/37576813
http://dx.doi.org/10.3389/fphar.2023.1106339
work_keys_str_mv AT lujing apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT gaojie apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT sunjing apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT wanghaiping apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT sunhuijuan apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT huangqian apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT zhangyao apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation
AT zhongshuo apolipoproteinaiattenuatesperitonealfibrosisassociatedwithperitonealdialysisbyinhibitingoxidativestressandinflammation